507 related articles for article (PubMed ID: 16844698)
1. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
[No Abstract] [Full Text] [Related]
2. [Lupus like syndrome induced by treatment with anti TNFalpha (infliximab): report of three cases].
Benucci M; Nenci G; Cappelletti C; Manfredi M
Recenti Prog Med; 2008; 99(7-8):363-6. PubMed ID: 18751615
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab-induced lupus erythematosus.
Martín JM; Ricart JM; Alcácer J; Rausell N; Arana G
Lupus; 2008 Jul; 17(7):676-8. PubMed ID: 18625641
[TBL] [Abstract][Full Text] [Related]
4. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
[TBL] [Abstract][Full Text] [Related]
5. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
Williams VL; Cohen PR
Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
[TBL] [Abstract][Full Text] [Related]
6. [Drug-induced systemic lupus erythematosus: reports to The Netherlands Pharmacovigilance Centre Lareb].
van Rijthoven AW; van Roon JA
Ned Tijdschr Geneeskd; 2007 Apr; 151(14):839; author reply 839. PubMed ID: 17469329
[No Abstract] [Full Text] [Related]
7. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
De Rycke L; Kruithof E; Van Damme N; Hoffman IE; Van den Bossche N; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF-alpha-induced systemic lupus syndrome.
Debandt M; Vittecoq O; Descamps V; Le Loët X; Meyer O
Clin Rheumatol; 2003 Feb; 22(1):56-61. PubMed ID: 12605321
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab-induced lupus erythematosus.
Al-Niaimi F
Eur J Dermatol; 2009; 19(4):380. PubMed ID: 19451046
[No Abstract] [Full Text] [Related]
10. Infliximab-induced SLE-like syndrome involving the lung and pleura.
Diri E; Tello W; Ratnoff WD; Nugent K
Lupus; 2007; 16(9):764-6. PubMed ID: 17728373
[No Abstract] [Full Text] [Related]
11. Development of systemic lupus erythematosus in a patient with rheumatoid arthritis following treatment conversion of infliximab to adalimumab.
Havel J; Aboutalebi S; Doughty L; Wirges M
J Drugs Dermatol; 2008 Aug; 7(8):796-8. PubMed ID: 18720701
[TBL] [Abstract][Full Text] [Related]
12. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.
Cavazzana I; Bobbio-Pallavicini F; Franceschini F; Bazzani C; Ceribelli A; Bravi E; Zingarelli S; Caporali R; Cattaneo R; Montecucco CM
Clin Exp Rheumatol; 2007; 25(5):676-83. PubMed ID: 18078613
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced lupus erythematosus in a patient treated with adalumimab.
Spillane AP; Xia Y; Sniezek PJ
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S114-6. PubMed ID: 17434034
[No Abstract] [Full Text] [Related]
15. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
Comby E; Tanaff P; Mariotte D; Costentin-Pignol V; Marcelli C; Ballet JJ
J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
[TBL] [Abstract][Full Text] [Related]
16. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma.
Liozon E; Ouattara B; Loustaud-Ratti V; Vidal E
Scand J Rheumatol; 2007; 36(6):484-6. PubMed ID: 18092275
[No Abstract] [Full Text] [Related]
17. Systemic listeriosis with adalimumab therapy.
Murphy G; Schmidt-Martin D; Hynes BG; Harney S
J Clin Rheumatol; 2009 Oct; 15(7):369-70. PubMed ID: 20009978
[No Abstract] [Full Text] [Related]
18. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
[TBL] [Abstract][Full Text] [Related]
19. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
[TBL] [Abstract][Full Text] [Related]
20. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
Nagashima T; Minota S
J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
[No Abstract] [Full Text] [Related]
[Next] [New Search]
